Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: Involvement of CD16 (FcγRIII) and CD11a/CD18 (LFA-1) on NK cells

Journal of Clinical Investigation

Volumn 98, Issue 12, 1996, Pages 2819-2826

  Wing, Mark G ^a,b   Moreau, Thibault ^b   Greenwood, Judith ^b   Smith, Richard M ^b   Hale, Geoff ^b   Isaacs, John ^b   Waldmann, Herman ^c   Lachmann, Peter J ^a   Compston, Alastair ^b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

adverse reaction; Fc receptor; humanized; monoclonal antibody; serotherapy

Indexed keywords

ALEMTUZUMAB; CD16 ANTIGEN; CYTOKINE; FC RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2B; INTERLEUKIN 6; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; HELPER CELL; HUMAN; HUMAN CELL; MONONUCLEAR CELL; NATURAL KILLER CELL; PRIORITY JOURNAL;

EID: 0030453977     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119110     Document Type: Article

References (43)

1. Hale, G., M-Q. Xia, H.P. Tighe, M.J.S. Dyer, and H. Waldmann. 1990. The CAMPATH-1 antigen (CDw52). Tissue Antigens. 35:118-127.
2. Hale, G., M. Clark, R. Marcus, G. Winter, M.J.S. Dyer, J.M. Phillips, L. Reichmann, and H. Waldmann. 1988. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH 1-H. Lancet. ii:1394-1399.
3. Dyer, M.J.S., G. Hale, F.G.J. Hayhoe, and H. Waldmann. 1989. Effects of CAMPATH 1-H in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood. 73:1431-1439.
4. Friend, P.J., P. Rebello, D. Oliveira, V. Manna, S.P. Cobbold, G. Hale, N.V. Jamieson, I. Jamieson, R.Y. Calne, D.T. Harris, and H. Waldmann. 1995. Successful treatment of renal allograft rejection with a humanised antilymphocyte monoclonal antibody. Transplant. Proc. 27:869-870.
5. Isaacs, J.D., R. Watts, B.L. Hazleman, G. Hale, M.T. Keogan, S.P. Cobbold, and H. Waldmann. 1992. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet. 340:748-752.
6. Mathieson, P.W., S.P. Cobbold, G. Hale, M.R. Clark, D.B.G. Oliveira, C.M. Lockwood, and H. Waldmann. 1990. Monoclonal antibody therapy in systemic vasculitis. N. Eng. J. Med. 323:250-254.
7. Lockwood, M.C., S. Thiru, J.D. Isaacs, G. Hale, and H. Waldmann. 1993. Long-term remission of intractable vasculitis with monoclonal antibody therapy. Lancet. 341:1620-1622.
8. Moreau, T., J. Thorpe, D. Miller, I. Moseley, G. Hale, H. Waldmann, D. Clayton, M.G. Wing, N. Scolding, and A. Compston. 1994. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet. 344:298-301.
9. Moreau, T., A. Coles, M.G. Wing, J. Isaacs, G. Hale, H. Waldmann, and A. Compston. 1996. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain. 119:225-237.
10. Riechmann, L., M. Clark, H. Waldmann, and G. Winter. 1988. Reshaping human antibodies for therapy. Nature (Lond.). 332:323-327.
11. Okusawa, S., K.B. Yancez, J.W.M. van der Meer, S. Endress, G. Lonnemann, K. Hefter, M.M. Frank, J.F. Burke, C.A. Dinarello, and J.A. Gelfand. 1988. C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1b and interleukin 1a. J. Exp. Med. 168:443-448.
12. Schermuck, S., and R. Burger. 1993. C3a and C3a-desArg induce release of IL-6 and TNFα from human monocytes. Mol. Immunol. 30(Suppl. 1):50.
13. Anegon, I., M.C. Cuturic, G. Trinchieri, and B. Perussia. 1988. Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J. Exp. Med. 167:452-472.
14. Bazzoni, F., M.A. Cassatella, C. Laudanna and F. Rossi. 1991. Phagocytosis of opsonised yeast induces TNFα mRNA and protein release by human polymorphonuclear leukocytes. J. Leuk. Biol. 50:223-228.
15. Stein, M., and S. Gordon. 1991. Regulation of tumor necrosis factor (TNF) release by peritoneal macrophages: role of cell stimulation and specific phagocytic plasma membrane receptors. Eur. J. Immunol. 21:431-437.
16. Rowan, W.C., G. Hale, J.P. Tite, and S.J. Brett. 1994. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes. Int. Immunol. 7:69-77.
17. Greenwood, J., M. Clark, and H. Waldmann. 1993. Structural motifs involved in human IgG antibody effector functions. Eur. J. Immunol. 23:1098-1104.
18. Wing, M.G., A.M.P. Montgomery, C. Harley, and P.J. Lachmann. 1990. Cytostasis of different tumours by a murine PPD-reactive T lymphocyte clone is mediated by interferon-gamma and tumour necrosis factor alone or synergistically. Clin. Exp. Immunol. 82:208-213.
19. Perussia, B., S. Starr, S. Abraham, V. Fanning, and G. Trinchieri. 1983. Human natural killer cells analysed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1. J. Immunol. 130:2133-2141.
20. Chatenoud, L., C. Ferran, C. Legendre, I. Thouard, S. Merite, A. Reuter, Y. Gevaert, H. Kries, P. Franchimont, and J.-F. Bach. 1990. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation. 49:697-702.
21. Arya, S.K., F. Wong-Staal, and R.C. Gallo. 1984. Dexamethasone-mediated inhibition of human T cell growth factor and γ-interferon messenger RNA. J. Immunol. 133:273-276.
22. Han, J., P. Thompson, and B. Beutler. 1990. Dexamethasone and pentoxifilline inhibit endotoxin induced cachectin/tumour necrosis factor synthesis at separate points in the signaling pathway. J. Exp. Med. 172:391-394.
23. Waage, A., G. Slupphaug, and P.B. Shalaly. 1990. Glucocorticoids inhibit the production of IL-6 from monocytes, endothelial cells and fibroblasts. Eur. J. Immunol. 20:2439-2443.
24. Wing, M.G., H. Waldmann, J. Isaacs, D.A.S. Compston, and G. Hale. 1996. Ex-vivo whole blood cultures for predicting cytokine-release syndrome: dependence on target antigen and antibody isotype. Ther. Immunol. In press.
25. Butler, T., and G. Moller. 1977. Mitogenic response of mouse spleen cells and gelation of limulus lysate by lipopolysaccharide of Yersinia pestis and evidence for neutralization of the lipopolysaccharide by polymyxin B. Infect. Immun. 18:400-404.
26. Morrison, D.C., and B.J. Curry. 1979. The use of polymyxin B and C3H/ HeJ mouse spleen cells as criteria for endotoxin contamination. J. Immunol. Methods. 27:83-92.
27. Cosimi, A.B., R.C. Burton, R.B. Colvin, G. Goldstein, F.L. Delmonico, M.P. LaQuaglia, R.H. Tolkoff-Rubin, R.H. Rubin, J.T. Herrin, and P.S. Russell. 1981. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation (Baltimore). 32:535-539.
28. Ortho Multicenter Transplant Study Group. 1985. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants, N. Engl. J. Med. 313:337-342.
29. 2 fragments of anti-CD3 monoclonal antibody as compared to whole antibody as immunosuppressive agents in mice. Transplant. Proc. 23: 270-271.
30. Parlevliet, K.J., I.J.M. ten Berge, S.-L. Yong, J. Surachno, J.M. Wilmink, and P.A. Schellekens. 1994. In vivo effects of IgA and Ig2a anti-CD3 isotype switch variants. J. Clin. Invest. 93:2519-2525.
31. Alegre, M.-L., A.M. Collins, V.L. Pulito, R.A. Brosius, W.C. Olson, R.A. Zivin, R. Knowles, J.R. Thistlethwaite, L.K. Jolliffe, and J.A. Bluestone. 1992. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanised" OKT3 monoclonal antibody. J Immunol. 148:3461-3468.
32. Alegre, M.-L., L.J. Peterson, D. Xu, H.A. Sattar, D.R. Jcyarajah, K. Knowalkowski, J.R. Thistlethwaite, R.A. Zivin, L. Jolliffe, and J.A. Bluestone. 1994. A non-activating "humanised" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation. 57:1537-1544.
33. Jefferis, R., J. Lund, and J. Pound. 1990. Molecular definition of interaction sites on human IgG for Fc receptors (FcγR). Mol. Immunol. 27:1237-1240.
34. Sarmay, G., J. Lund, Z. Rozsnyay, J. Gergley, and R. Jefferis. 1992. Mapping and comparison of the interaction sites on the Fc region of IgG responsible for triggering antibody dependent cellular cytotoxicity (ADCC) through different types of human Fcγ receptor. Mol. Immunol. 29:633-639.
35. Bauer, J., U. Ganter, U. Jacobshagen, T. Hirano, T. Matsuda, T. Kishimoto, T. Andus, G. Acs, W. Gerok, and G. Ciliberto. 1988. Regulation of interleukin-6 expression in cultured human monocytes and monocyte-derived macrophages. Blood. 72:1134-1140.
36. Navarro, S., N. Debili, J.-F. Bernaudin, W.V. Vainchenker, and J. Doly. 1989. Regulation of the expression of IL-6 in human monocytes. J. Immunol. 142:4339-4345.
37. Shalaby, M.R., A. Waage, and T. Espevik. 1989. Cytokine regulation of interleukin-6 production by human endothelial cells. Cell. Immunol. 121:372-382.
38. Lanier, L.L., G. Yu, and J.H. Phillips. 1989. Co-association of CD3ζ with a receptor (CD16) for IgG Fc on human natural killer cells. Nature (Lond.). 342:803-805.
39. Letourneur, O., I.C.S. Kennedy, A.T. Brini, J.R. Ortaldo, J.J. O'Shea, and J.P. Kinet. 1991. Characterisation of the family of dimers associated with Fc receptors (FcεR1 and FcγRIII). J. Immunol. 147:2652-2656.
40. Fraser, J.D., D. Straus, and A. Weiss. 1993. Signal transduction events leading to T-cell lymphokine gene expression. Immunol. Today. 14:357-362.
41. Nishimura, T., and T. Itoh. 1988. High expression of lymphocyte function associated antigen-1 (LFA-1) on in vivo natural killer cells. Eur. J. Immunol. 18:2077-2080.
42. Robertson, M.J., M.A. Caliguri, T.J. Manley, H. Levine, and J. Ritz. 1990. Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis. J. Immunol. 145:3194-3201.
43. Melero, I., M.A. Balboa, J.L. Alonso, E. Yague, J.P. Pivel, F.S. Sanchez-Madrid, and M. Lopez-Botet. 1993. Signaling through LFA-1 leucocyte integrin actively regulates intercellular adhesion and tumour necrosis factor-a production in natural killer cells. Eur. J. Immunol. 23:1859-1865.